Keywords: Biogen Idec, First-quarter 2012 financial results

Biogen Idec 1st-qtr sales up 7% but fail to match expectations

Article | 02 May 2012

Print This

US biotech company Biogen Idec (Nasdaq: BIIB) post first-quarter 2012 sales of $1.29 billion, a rise of 7%, but slightly below analysts’ ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in